# Agent 6 Benchmark Report - 30_multi_turn

**Generated:** 2026-06-03 20:43:36
**Agent:** 6
**Category:** 30_multi_turn

## Executive Summary

| Metric | Value |
|--------|-------|
| Total Tests | 9 |
| Passed | 5 |
| Failed | 4 |
| Pass Rate | 55.6% |
| Avg Score | 0.816 |

### Failure Root Causes

| Root Cause | Count | % of Failures | Severity |
|------------|-------|---------------|----------|
| too_brief | 2 | 50.0% | P2 |
| wrong_answer | 2 | 50.0% | P2 |

## Detailed Results

### ✅ MT001

**Input:** Turn 1: I have a prostate cancer patient. Turn 2: The CT shows a 35cc prostate. Turn 3: What seed count do you recommend?...

**Response:**
> ## Seed Count Recommendation for 35cc Prostate**General guideline:** ~1 seed per cc of prostate volume, adjusted by seed activity.| Seed Activity | Estimated Seed Count | Notes ||---------------|---------------------|-------|| 0.4 mCi (U) | **40–45 seeds** | Lower activity, more peripheral loading || 0.45 mCi (U) | **35–40 seeds** | Standard practice || 0.5 mCi (U) | **30–35 seeds** | Higher activity, fewer seeds |**Clinical factors to adjust count:**- **Monotherapy (144–145 Gy):** Higher total activity needed- **Boost therapy (108–110 Gy):** Lower activity acceptable- **Prostate volume + margin** (~5mm) determines actual seed placement- **Anterior-posterior dimension** affects anterior seed requirement**Quick calculation:**```Total activity (U...

**Scores:**
- Total: 1.00
- Keyword: 1.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![MT001](../screenshots/30_MT001.png)

---

### ✅ MT002

**Input:** Turn 1: Analyze this CT. Turn 2: Now segment the CTV. Turn 3: What about the OAR?...

**Response:**
> **No CT files are currently loaded.** I cannot perform image analysis or segmentation without loaded imaging data.## From Medical Knowledge: CTV & OAR Delineation for Prostate Brachytherapy### CTV (Clinical Target Volume)Per **ABS/ASTRO** guidelines for prostate LDR brachytherapy:- **CTV = Prostate gland** (no margin added for MRI-CT fusion; often used 0mm margin)- Typically includes proximal seminal vesicles when involved- Recommend **MRI fusion** for improved accuracy when available### OARs for Prostate BrachytherapyKey organs at risk with typical dose constraints:| Organ | Constraint | Guideline ||-------|------------|-----------|| **Urethra** | D10 < 200% prescription; V...

**Scores:**
- Total: 1.00
- Keyword: 1.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![MT002](../screenshots/30_MT002.png)

---

### ❌ MT004

**Input:** Turn 1: The plan score is 72. Turn 2: Can you optimize it? Turn 3: What changed after optimization?...

**Response:**
> Tools executed. Check the execution trace above for results....

**Scores:**
- Total: 0.55
- Keyword: 0.00
- Completeness: 0.50
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![MT004](../screenshots/30_MT004.png)

**Failure Analysis:**
- Root Cause: too_brief
- Description: Response too short (60 chars)

---

### ❌ MT005

**Input:** Turn 1: 分割完成了吗？Turn 2: 结果怎么样？Turn 3: 帮我导出报告。...

**Response:**
> ⚠️ 未能执行当前没有加载CT文件，无法进行分割或生成报告。请先上传CT文件，然后我才能：执行结构分割分析分割结果导出临床报告...

**Scores:**
- Total: 0.55
- Keyword: 0.00
- Completeness: 0.50
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![MT005](../screenshots/30_MT005.png)

**Failure Analysis:**
- Root Cause: too_brief
- Description: Response too short (63 chars)

---

### ✅ MT006

**Input:** Turn 1: What's the V100? Turn 2: And V200? Turn 3: Is the plan safe to export?...

**Response:**
> **No plan data available in current session.** Cannot retrieve V100, V200, or run safety validation.**General clinical targets for prostate LDR brachytherapy:**| Metric | Target | Guideline ||--------|--------|-----------|| V100 | ≥95% | GEC-ESTRO / ABS || V200 | 15–35% | ABS Recommended || D90 | 100–120% of prescription | ABS / GEC-ESTRO |**Typical OAR constraints:**- **Urethra D10**: <130% of prescription- **Rectum D2cc**: <65 Gy (for 145 Gy prescription)- **Bladder D2cc**: <65 Gy---**To proceed:** Load a treatment plan or upload CT with structures, then I can:1. Calculate actual V100, V200, D902. Evaluate OAR doses3. Run `safety_validator` for pre-export check...

**Scores:**
- Total: 1.00
- Keyword: 1.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![MT006](../screenshots/30_MT006.png)

---

### ❌ MT007

**Input:** Turn 1: 我有一个宫颈癌病例。Turn 2: 用HDR方案。Turn 3: 剂量约束是什么？...

**Response:**
> ## 宫颈癌HDR近距离放疗剂量约束根据GEC-ESTRO、ABS及NCCN指南，宫颈癌HDR主要危及器官约束如下：### 靶区处方| 参数 | 剂量 ||------|------|| 高危CTV (HR-CTV) | 4-6 Gy × 5次（部分病例可调） || 中危CTV (IR-CTV) | 参考点剂量 3-4 Gy × 5次 |### OAR剂量约束 (以5次分割为例)| 器官 | 约束 | 依据 ||------|------|------|| **直肠** | D2cc ≤ 65-75 Gy | GEC-ESTRO || **膀胱** | D2cc ≤ 75-80 Gy | GEC-ESTRO || **乙状结肠** | D2cc ≤ 65-70 Gy | GEC-ESTRO || **小肠** | D2cc ≤ 60 Gy | QUANTEC || **输尿管** | D0.5cc ≤ 80 Gy | ABS推荐...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![MT007](../screenshots/30_MT007.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ MT008

**Input:** Turn 1: Show me the DVH. Turn 2: The rectum looks too high. Turn 3: Can you adjust the plan?...

**Response:**
> **⚠️ 无法显示DVH或调整计划** — 当前没有加载患者数据或治疗计划。---## 宫颈癌HDR近距离治疗剂量约束（基于GEC-ESTRO/ABS指南）### 典型处方方案| 方案 | 剂量/次数 ||------|----------|| 5.5 Gy × 5次 | EQD2总剂量 ~45 Gy || 6 Gy × 4次 | EQD2总剂量 ~44 Gy || 7 Gy × 3次 | EQD2总剂量 ~42 Gy |### OAR剂量约束（EQD2）| 器官 | D2cc | D0.1cc | 参考 ||------|------|--------|------|| **直肠** | ≤65-70 Gy | ≤75-80 Gy | GEC-ESTRO || **膀胱** | ≤70-75 Gy | ≤80-85 Gy | GEC-ESTRO || **乙状结肠** | ≤65 Gy | — | EMBRACE II || **小肠** | ≤60 Gy | — | EMBRACE...

**Scores:**
- Total: 0.74
- Keyword: 0.25
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![MT008](../screenshots/30_MT008.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ MT009

**Input:** Turn 1: 帮我找一下类似的病例。Turn 2: 那个病例的V100是多少？Turn 3: 我们能达到同样的水平吗？...

**Response:**
> 本地病例库中未找到匹配的宫颈癌HDR病例。**宫颈癌HDR近距离治疗的标准剂量目标：**| 参数 | 目标值 | 依据 ||------|--------|------|| **D90 (HR-CTV)** | 处方剂量 100% | GEC-ESTRO || **V100 (HR-CTV)** | ≥95% | GEC-ESTRO / ABS || **V200** | <50% (不宜过高) | 临床经验 || **EQD2 (HR-CTV)** | ≥85 Gy (取决于分割) | ABS |**典型分割方案 (ICRU 89)：**- 4 fractions × 7 Gy- 5 fractions × 6 Gy  - 3 fractions × 8.5 Gy**OAR约束 (EQD2)：**| 器官 | 限制 ||------|------|| 直肠 D2cc | <65...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![MT009](../screenshots/30_MT009.png)

---

### ✅ MT010

**Input:** Turn 1: I need help with a lung case. Turn 2: The tumor is in the left lower lobe. Turn 3: What's the prescription dose?...

**Response:**
> **⚠️ Note:** Lung cancer is typically treated with **SBRT/EBRT**, not brachytherapy. However, I can provide guidance:## Lung Cancer Treatment Options| Modality | Typical Prescription | Fractions ||----------|---------------------|-----------|| **SBRT** (most common) | 50 Gy | 5 fx || | 54 Gy | 3 fx || | 48 Gy | 4 fx || | 60-70 Gy | 8-10 fx (central tumors) || **Conventional EBRT** | 60-66 Gy | 30-33 fx || **Endobronchial BT** (rare) | 5-7 Gy | 3-5 fx |## Left Lower Lobe Considerations- Peripheral tumors: Standard SBRT doses apply- Central/hilar tumors: Consider dose reduction or alternative fractionation (AAPM TG-101)---**Questions to refine:**1. Is this **endobronchial brachy...

**Scores:**
- Total: 1.00
- Keyword: 1.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![MT010](../screenshots/30_MT010.png)

---

